Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28434648

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2017 Jun 24
First author
El-Khoueiry AB

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2017 Jul;14(7):392. doi: 10.1038/nrclinonc.2017.70.
    note
    Source null
    related pmid
    28485409
    relationship
    Comment in
  2. citation
    Nat Rev Gastroenterol Hepatol. 2017 Jun;14(6):326. doi: 10.1038/nrgastro.2017.62.
    note
    Source null
    related pmid
    28487550
    relationship
    Comment in

Authors and identifiers

  1. name
    El-Khoueiry AB
    type
    Author
  2. name
    Sangro B
    type
    Author
  3. name
    Yau T
    type
    Author
  4. name
    Crocenzi TS
    type
    Author
  5. name
    Kudo M
    type
    Author
  6. name
    Hsu C
    type
    Author
  7. name
    Kim TY
    type
    Author
  8. name
    Choo SP
    type
    Author
  9. name
    Trojan J
    type
    Author
  10. name
    Welling TH Rd
    type
    Author
  11. name
    Meyer T
    type
    Author
  12. name
    Kang YK
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    El-Khoueiry AB
    type
    Author
  2. name
    Sangro B
    type
    Author
  3. name
    Yau T
    type
    Author
  4. name
    Crocenzi TS
    type
    Author
  5. name
    Kudo M
    type
    Author
  6. name
    Hsu C
    type
    Author
  7. name
    Kim TY
    type
    Author
  8. name
    Choo SP
    type
    Author
  9. name
    Trojan J
    type
    Author
  10. name
    Welling TH Rd
    type
    Author
  11. name
    Meyer T
    type
    Author
  12. name
    Kang YK
    type
    Author
bibliography ids
  1. nci-bib-d39eaa123f52439f6bfdcf66
book metadata
content sha256
12b18707dff1bb8f40f38e6cc886531d95057f4cfe362f803bbff2617ffba9fb
document type
citation
dois
  1. 10.1016/S0140-6736(17)31046-2
electronic publication date
display
2017 Apr 20
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:28434648
immutable id
pubmed:28434648@12b18707dff1bb8f40f38e6cc886531d95057f4cfe362f803bbff2617ffba9fb
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10088
name
Lancet (London, England)
nlm unique id
2985213R
pages
2492-2502
volume
389
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2017 Jul;14(7):392. doi: 10.1038/nrclinonc.2017.70.
    note
    Source null
    related pmid
    28485409
    relationship
    Comment in
  2. citation
    Nat Rev Gastroenterol Hepatol. 2017 Jun;14(6):326. doi: 10.1038/nrgastro.2017.62.
    note
    Source null
    related pmid
    28487550
    relationship
    Comment in
outcomes validated
false
pmid
28434648
provenance
batch id
1c173f0e18be0c6d461b
provider
NCBI PubMed ESummary
record sha256
3e05733d916075e8868195c63d95c37595daed9fa482a20b602d8a91cba37d7e
response sha256
27a6f8bb5d49a8d376b07e1b1768913c558986bf73de92cdd65c8f05a5fa1e61
retrieved at
2026-09-09T23:47:25.975513+00:00
publication date
display
2017 Jun 24
precision
day
year
2017
publication types
  1. Clinical Trial, Phase I
  2. Clinical Trial, Phase II
  3. Journal Article
  4. Multicenter Study
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28434648/
title
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Preserved source evidence · Not medical advice